ID
4848
Beschrijving
see http://clinicaltrials.gov/ct2/show/study/NCT00048295 ISIS 2302 is an antisense oligonucleotide drug that reduces the production of a specific protein called intercellular adhesion molecule (ICAM-1), a substance that plays a significant role in the increase of inflammation. People with Crohn’s disease have been shown to over-produce ICAM-1 in their gut tissues. Alicaforsen works by blocking ICAM-1 messenger RNA, the “instruction” molecule that is required for the production of ICAM-1 protein. This trial will examine effects of alicaforsen delivered by 2-hour intravenous infusion over a four-week period, compared to a placebo. Patients may remain on stable background 5-ASA, antibiotic, or immunosuppressive drugs, and prednisone (or equivalent) at </= 30 mg per day.
Link
http://clinicaltrials.gov/ct2/show/study/NCT00048295
Trefwoorden
Versies (1)
- 11-04-14 11-04-14 - Julian Varghese
Geüploaded op
11 april 2014
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility NCT00048295 Crohns Disease
Eligibility NCT00048295
- StudyEvent: Eligibility
Beschrijving
Exclusion
Beschrijving
Severe intestinal stenosis
Datatype
boolean
Alias
- UMLS CUI-1
- C0521587
Beschrijving
External fistulization
Datatype
boolean
Alias
- UMLS CUI-1
- C0016169
Beschrijving
Infection
Datatype
boolean
Alias
- UMLS CUI-1
- C0009450
Beschrijving
Malignancy
Datatype
boolean
Alias
- UMLS CUI-1
- C0006826
Beschrijving
Bleeding problem
Datatype
boolean
Alias
- UMLS CUI-1
- C0005779
Similar models
Eligibility NCT00048295
- StudyEvent: Eligibility
C1456820 (UMLS CUI-2)
C0021469 (UMLS CUI-3)